Drug Portfolio

About Novolimus

Novolimus™ is a metabolite of the drug Sirolimus, a novel mTOR inhibitor macrolytic lactone with anti-proliferative and anti-inflammatory properties developed by Elixir Medical. The macrocyclic lactone drugs represent the most widely utilized drug family for drug-eluting stent applications and have an established safety and efficacy profile.

About Sirolimus

Sirolimus is the most widely known mTOR inhibitor with a well-established safety and effectiveness profile in various treatment applications:

  • Drug-eluting stents
  • Transplant
  • Oncology

Novolimus and Sirolimus have been studied as part of Elixir Medical’s Clinical Programs. These clinical trials for DynamX, DESyne®, DESyne® BD and the fully resorbable DESolve® and DESolve® Cx scaffolds have resulted in excellent clinical outcomes and sustained safety and effectiveness.

The DESyne BD Novolimus-Eluting Coronary Stent System represented a significant advancement in biodegradable coating technology, eliminating the need for a primer coating and achieving a bare metal surface within six to nine months, while providing excellent DES results.

The DESolve Scaffold System was a state-of-the-art novolimus-eluting bioresorbable coronary scaffold system that represented the next generation in scaffold technology. Unlike conventional metal stents, DESolve degraded in about one year, leaving behind a thin neointimal lining and well-maintained lumen – similar to a de novo vessel. DESolve CX Plus was an advancement of the DESolve Scaffold System, designed to maintain the platform’s unique polymer characteristics while improving deliverability.7

*These products are not approved by the United States Food and Drug Administration (FDA).

PMN 571 Rev A
Elixir-Medical-Corporation-Coronary-Device

Corporate Headquarters
920 N. McCarthy Blvd
Milpitas, CA 95035 U.S.
+1.408.636.2000
info@elixirmedical.com

Elixir, Innovation for Life and DESyne are registered trademarks, and DynamX a trademark, in the US and internationally for Elixir Medical Corporation.
DynamX Coronary Bioadaptor System and DESyne X2 Novolimus Eluting Coronary Stent System are CE Mark approved.
©2020 Elixir Medical. All rights reserved.
International (OUS) Use Only. DynamX and DESyne X2 are intended to improve coronary luminal diameter in patients with symptomatic ischemic heart disease due to discrete de novo native coronary artery lesions. CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device.

Sign up to receive news and information about Elixir Medical, our products and other relevant information as it becomes available.